retatrutide gip glp-1 glucagon receptor agonist Glucagon-like peptide-1 receptor: mechanisms and advances in therapy Retatrutide | GLP-1R/GIPR/GCGR ligand |

Weight loss on a GLP-1 is a gradual and healthy process

While both clinical and real-world results have shown these medications can improve heart health, new research has found a downside: People who stop taking them quickly lose these improvements and may be at an increased risk of heart attack, stroke, and even death compared with people who stay on them consistently

For example, researchers often assess its influence on insulin secretion, glucose tolerance, cellular response behavior, and various weight-related biochemical patterns

Enter John Eng, a physician-researcher working at the James J

Given the heterogeneity of AUD and the complexity of the effect of alcohol on neural and physiological systems, there is a critical need to explore alternative pharmacotherapies that act through novel mechanisms

This may contribute to the salutary cardiovascular protective effects of the GLP-1 receptor agonists seen in multiple clinical trials